Kymera Therapeutics KYMR
$115.31 −$4.08 (-3.42%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $124.06 +7.59%
Open$117.89
Prev close$119.39
Day range$114.40 – $119.60
Volume1.28M
Market cap$9.84B
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±4.8%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+11.1%
Worst reaction-15.1%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 29 Oct 2026 | Pre Market | ±19.6% | +0.07% | Within range |
| 2026/Q2 | 5 Aug 2026 | Pre Market | ±10.0% | +1.04% | Within range |
| 2026/Q1 | 30 Apr 2026 | Pre Market | ±10.1% | -0.54% | Within range |
| 2025/Q4 | 26 Feb 2026 | Pre Market | ±11.5% | +4.80% | Within range |
| 2025/Q3 | 4 Nov 2025 | Pre Market | ±15.7% | +0.32% | Within range |
| 2025/Q2 | 11 Aug 2025 | Pre Market | ±19.3% | -7.24% | Within range |
| 2025/Q1 | 9 May 2025 | Pre Market | ±23.7% | -2.27% | Within range |
| 2024/Q4 | 27 Feb 2025 | Pre Market | ±18.7% | -14.45% | Within range |
| 2024/Q3 | 31 Oct 2024 | Pre Market | ±18.7% | -3.15% | Within range |
| 2024/Q2 | 7 Aug 2024 | Pre Market | ±22.9% | -2.68% | Within range |
| 2024/Q1 | 2 May 2024 | Pre Market | ±13.7% | +0.17% | Within range |
| 2023/Q4 | 22 Feb 2024 | Pre Market | – | +4.71% | – |
| 2023/Q3 | 2 Nov 2023 | Pre Market | – | +4.59% | – |
| 2023/Q2 | 3 Aug 2023 | Pre Market | ±14.2% | +11.07% | Within range |
| 2023/Q1 | 4 May 2023 | Pre Market | ±26.3% | -15.08% | Within range |
| 2022/Q4 | 23 Feb 2023 | Pre Market | ±14.9% | +5.17% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00-100.0% YoY
Operating profit-$147.23M-66.1% YoY
Net profit-$132.00M-60.6% YoY
Diluted EPS-$1.32-40.4% YoY
Free cash flow-$78.23M-186.6% YoY
Operating cash flow-$77.91M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Operating margin-396.0%
Net margin-341.8%
Return on equity-27.3%
Return on assets-24.4%
Return on invested capital-29.8%
Current ratio11.13
Liabilities / assets8.6%
Cash & investments$971.21M
Total debt$63.02M
Net cash (debt)$908.20M
No comments yet — be the first to weigh in on KYMR.
Sign in to join the discussion.